Curis Earnings Surge Cant Stop 5.39% Stock Slide

Curis (CRIS) reported a dramatic turnaround in fiscal 2025 Q4, with net income jumping 301.2% year-over-year to $19.36 million, driven by a $27.2 million one-time gain from Erivedge royalty sales. The stock price, however, fell 5.39% post-earnings as investors reacted to concerns over no recurring revenue in 2026.

Revenue

Total revenue declined 66.0% year-over-year to $1.14 million in 2025 Q4, reflecting the impact of the Erivedge sale and transition to a development-stage business model.

Earnings/Net Income

The company returned to profitability with an EPS of $1.50, reversing from a $1.13 loss in 2024 Q4. Net income surged to $19.36 million, a 301.2% positive swing, fueled by the one-time gain and cost reductions. The 301.2% net income increase and positive EPS shift reflect a strong turnaround despite revenue challenges.

Price Action

CRIS shares fell 3.25% in the latest trading day, 19.81% in the week, and 35.59% month-to-date as of March 24, 2026.

Post-Earnings Price Action Review

A backtest of buying CRIS shares after QoQ revenue declines on earnings dates and holding 30 days from 2022–2026 yielded -18.90% returns versus a 58.28% benchmark gain. Key drivers of underperformance included high volatility (79.58%), negative EPS surprises (e.g., -10.90% price drop in Q1 2023), and investor skepticism over post-Erivedge revenue sustainability. Despite a $27.2M gain in Q4 2025, the stock fell 5.39% post-earnings due to concerns about 2026’s revenue outlook.

CEO Commentary

Curis CEO emphasized operational efficiency and pipeline progress, stating, “Our Q4 results demonstrate the value of strategic decisions like Erivedge’s sale. While revenue transition is challenging, we remain focused on advancing emavusertib trials and securing regulatory pathways.”

Guidance

The company provided no specific revenue guidance for 2026 but noted cash runway extends into H2 2027 as it advances clinical programs.

Additional News

1. Erivedge Royalty Sale: A $27.2 million one-time gain in Q4 2025 offset revenue declines but eliminated a recurring income stream.

2. Analyst Price Target: H.C. Wainwright reiterated a $17 price target (2197.92% upside from $0.76) in June 2025, citing pipeline potential.

3. No Dividends: Curis has not declared dividends historically, with focus on capital preservation amid high R&D costs (~$28.3 million in 2025).

All statistics sourced from Curis filings and Investing.com reports.